Christopher R Friese1, Yun Li2, Irina Bondarenko2, Timothy P Hofer3,4, Kevin C Ward5, Ann S Hamilton6, Dennis Deapen6, Allison W Kurian7,8, Steven J Katz3,9. 1. Department of Systems, Populations, and Leadership, School of Nursing, University of Michigan, Ann Arbor, Michigan. 2. Department of Biostatistics, School of Public Health, University of Michigan, Ann Arbor, Michigan. 3. Division of General Medicine, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan. 4. Health Services Research and Development Center of Excellence, Ann Arbor Veterans Affairs Medical Center, Ann Arbor, Michigan. 5. Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, Georgia. 6. Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California. 7. Department of Medicine, Stanford University Medical Center, Palo Alto, California. 8. Department of Health Research and Policy, Stanford University Medical Center, Palo Alto, California. 9. Department of Health Management and Policy, School of Public Health, University of Michigan, Ann Arbor, Michigan.
Abstract
BACKGROUND: The 21-gene recurrence score (RS) assay stratifies early-stage, estrogen receptor-positive breast cancer by recurrence risk. Few studies have examined the ways in which physicians use the RS to recommend adjuvant systemic chemotherapy or patients' experiences with testing and decision making. METHODS: This study surveyed 3880 women treated for breast cancer in 2013-2014; they were identified from the Los Angeles County and Georgia Surveillance, Epidemiology, and End Results registries (response rate, 71%). Women reported chemotherapy recommendations, the receipt of chemotherapy, testing experiences, and decision satisfaction. Registries linked the tumor data, RS, and surveys. Regression models examined factors associated with chemotherapy recommendations and receipt by the RS and subgroups. RESULTS: There were 1527 patients with stage I/II, estrogen receptor/progesterone receptor-positive, human epidermal growth factor 2-negative disease: 778 received an RS (62.6% of patients with node-negative, favorable disease, 24.3% of patients with node-negative, unfavorable disease, and 13.0% of patients with node-positive disease; P < .001). Overall, 47.2% of the patients received a recommendation against chemotherapy, and 40.5% received a recommendation for it. RS results correlated with recommendations: nearly all patients with high scores (31-100) received a chemotherapy recommendation (86.9%-96.5% across clinical subgroups), whereas the majority of the patients with low-risk results (0-18) received a recommendation against it (65.9%-78.2% across subgroups). Most patients with high RSs received chemotherapy (87.0%, 91.1%, and 100% across subgroups), whereas few patients with low scores received it (2.9%, 9.5%, and 26.6% across subgroups). There were no substantial racial/ethnic differences in testing or treatment. Women were largely satisfied with the RS and chemotherapy decisions. CONCLUSIONS: Oncologists use the RS to personalize treatment, even for those with node-positive disease. High satisfaction and an absence of disparities in testing and treatment suggest that precision-medicine advances have improved systemic breast cancer treatment. Cancer 2017;43-51.
BACKGROUND: The 21-gene recurrence score (RS) assay stratifies early-stage, estrogen receptor-positive breast cancer by recurrence risk. Few studies have examined the ways in which physicians use the RS to recommend adjuvant systemic chemotherapy or patients' experiences with testing and decision making. METHODS: This study surveyed 3880 women treated for breast cancer in 2013-2014; they were identified from the Los Angeles County and Georgia Surveillance, Epidemiology, and End Results registries (response rate, 71%). Women reported chemotherapy recommendations, the receipt of chemotherapy, testing experiences, and decision satisfaction. Registries linked the tumor data, RS, and surveys. Regression models examined factors associated with chemotherapy recommendations and receipt by the RS and subgroups. RESULTS: There were 1527 patients with stage I/II, estrogen receptor/progesterone receptor-positive, human epidermal growth factor 2-negative disease: 778 received an RS (62.6% of patients with node-negative, favorable disease, 24.3% of patients with node-negative, unfavorable disease, and 13.0% of patients with node-positive disease; P < .001). Overall, 47.2% of the patients received a recommendation against chemotherapy, and 40.5% received a recommendation for it. RS results correlated with recommendations: nearly all patients with high scores (31-100) received a chemotherapy recommendation (86.9%-96.5% across clinical subgroups), whereas the majority of the patients with low-risk results (0-18) received a recommendation against it (65.9%-78.2% across subgroups). Most patients with high RSs received chemotherapy (87.0%, 91.1%, and 100% across subgroups), whereas few patients with low scores received it (2.9%, 9.5%, and 26.6% across subgroups). There were no substantial racial/ethnic differences in testing or treatment. Women were largely satisfied with the RS and chemotherapy decisions. CONCLUSIONS: Oncologists use the RS to personalize treatment, even for those with node-positive disease. High satisfaction and an absence of disparities in testing and treatment suggest that precision-medicine advances have improved systemic breast cancer treatment. Cancer 2017;43-51.
Authors: Arnold L Potosky; Suzanne C O'Neill; Claudine Isaacs; Huei-Ting Tsai; Calvin Chao; Chunfu Liu; Bola F Ekezue; Nandini Selvam; Larry G Kessler; Yingjun Zhou; Marc D Schwartz Journal: Cancer Date: 2015-08-20 Impact factor: 6.860
Authors: Michaela A Dinan; Xiaojuan Mi; Shelby D Reed; Bradford R Hirsch; Gary H Lyman; Lesley H Curtis Journal: JAMA Oncol Date: 2015-05 Impact factor: 31.777
Authors: Mark N Levine; Jim A Julian; Philippe L Bedard; Andrea Eisen; Maureen E Trudeau; Brian Higgins; Louise Bordeleau; Kathleen I Pritchard Journal: J Clin Oncol Date: 2015-11-23 Impact factor: 44.544
Authors: Megan C Roberts; Morris Weinberger; Stacie B Dusetzina; Michaela A Dinan; Katherine E Reeder-Hayes; Lisa A Carey; Melissa A Troester; Stephanie B Wheeler Journal: J Clin Oncol Date: 2015-11-23 Impact factor: 44.544
Authors: Megan C Roberts; Morris Weinberger; Stacie B Dusetzina; Michaela A Dinan; Katherine E Reeder-Hayes; Melissa A Troester; Lisa A Carey; Stephanie B Wheeler Journal: Breast Cancer Res Treat Date: 2015-07-28 Impact factor: 4.872
Authors: Shelly S Lo; Patricia B Mumby; John Norton; Karen Rychlik; Jeffrey Smerage; Joseph Kash; Helen K Chew; Ellen R Gaynor; Daniel F Hayes; Andrew Epstein; Kathy S Albain Journal: J Clin Oncol Date: 2010-01-11 Impact factor: 44.544
Authors: Michael J Hassett; Samuel M Silver; Melissa E Hughes; Douglas W Blayney; Stephen B Edge; James G Herman; Clifford A Hudis; P Kelly Marcom; Jane E Pettinga; David Share; Richard Theriault; Yu-Ning Wong; Jonathan L Vandergrift; Joyce C Niland; Jane C Weeks Journal: J Clin Oncol Date: 2012-05-14 Impact factor: 44.544
Authors: Lu Zhang; Jessica King; Xiao-Cheng Wu; Mei-Chin Hsieh; Vivien W Chen; Qingzhao Yu; Elizabeth Fontham; Michelle Loch; Lori A Pollack; Tekeda Ferguson Journal: Cancer Epidemiol Date: 2018-11-08 Impact factor: 2.984
Authors: Allison W Kurian; Irina Bondarenko; Reshma Jagsi; Christopher R Friese; M Chandler McLeod; Sarah T Hawley; Ann S Hamilton; Kevin C Ward; Timothy P Hofer; Steven J Katz Journal: J Natl Cancer Inst Date: 2018-05-01 Impact factor: 13.506
Authors: L M McSorley; M Tharmabala; F Al Rahbi; K McSorley; S Chew; D Evoy; J G Geraghty; R S Prichard; J Rothwell; D P McCartan; E W McDermott; M Keane; M J Kennedy; S O'Reilly; S J Millen; J P Crown; L M Smyth; C M Kelly; C M Quinn; J M Walshe Journal: Breast Cancer Res Treat Date: 2021-04-09 Impact factor: 4.872
Authors: Kelsey H Natsuhara; Katya Losk; Tari A King; Nancy U Lin; Kristen Camuso; Mehra Golshan; Stephen Pochebit; Jane E Brock; Craig A Bunnell; Rachel A Freedman Journal: Oncologist Date: 2018-08-03
Authors: Steven J Katz; Lauren P Wallner; Paul H Abrahamse; Nancy K Janz; Kathryn A Martinez; Dean A Shumway; Ann S Hamilton; Kevin C Ward; Kenneth A Resnicow; Sarah T Hawley Journal: Cancer Date: 2017-04-11 Impact factor: 6.921
Authors: Steven J Katz; Sarah T Hawley; Irina Bondarenko; Reshma Jagsi; Kevin C Ward; Timothy P Hofer; Allison W Kurian Journal: Breast Cancer Res Treat Date: 2017-07-08 Impact factor: 4.624